Work

Successful Treatment of BRAF-Mutated Metastatic Melanoma in an Advanced-Age Patient with Dabrafenib and Trametinib: A Case Report and Literature Review

Year: 2025

Type: article

Abstract: Introduction: BRAF and MEK inhibitors, specifically dabrafenib and trametinib, have substantially improved treatment outcomes in metastatic melanoma. However, their use in advanced-age patients remains insufficiently studied. Case Presentation: A 90-year-old man with a history of wide excision for cutaneous melanoma developed liver metastases. Core needle biopsy confirmed the presence of a BRAF V600E mutation. The patient was treated with dabrafenib (150 mg twice daily) and trametinib (2 mg once daily). After 6 months, he achieved complete remission of liver metastases, experiencing only mild adverse events, including grade 1 pyrexia and diarrhea. Conclusion: This case report demonstrates that dabrafenib-trametinib combination therapy is an effective and well-tolerated treatment option for BRAF-mutated metastatic melanoma in advanced-age patients.

Source: Case Reports in Oncology

DOI: 10.1159/000549686

Authors: Cheol-Sik Kim, Jae-Joon Kim, Sang-Bo Oh

Institutions: Pusan National University Yangsan Hospital, Pusan National University

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,170